OrbiMed has been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Orbimed’s team of over 80 distinguished scientific, medical, investment and other professionals manage approximately $14 billion across public and private company investments worldwide.

OrbiMed invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made in one of three strategies: public equity, private equity, and royalty opportunities.

OrbiMed manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide.

OrbiMed’s private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build portfolio companies. Geographic focus includes North America, Asia, Europe and Israel.

OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, OrbiMed can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan.

TVI (formerly Takeda Research Investment, Inc.), was founded in 2001 with the vision to extend Takeda’s reach into the Global scientific community and forge strategic relationships that complement and expand internal R&D capabilities.

The change in name to Takeda Ventures, Inc. in 2011 reflects an intention to further leverage TVI’s venture networks to engage with new scientific and business avenues for Takeda, using strategic venturing to enable staged-entry into new spaces in a fully-informed manner.

Takeda’s aim is to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and the provision of access to the resources of a multinational pharmaceutical company